{
    "clinical_study": {
        "@rank": "129532", 
        "arm_group": [
            {
                "arm_group_label": "BI 655066", 
                "arm_group_type": "Experimental", 
                "description": "A patient to receive multiple dose of BI 655066"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A patient to receive multiple dose of placebo"
            }, 
            {
                "arm_group_label": "BI 655066 SC", 
                "arm_group_type": "Experimental", 
                "description": "A patient to receive multiple SC dose of BI 655066"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a proof of concept, multi-center, randomized, double-blind,\n      placebo-controlled, parallel-group phase 2 dose-ranging study of BI 655066, an IL-23 p19\n      antagonist monoclonal antibody, in patients with moderately to severely active Crohn's\n      disease."
        }, 
        "brief_title": "Efficacy, Safety and Pharmacokinetics of BI 655066 in Patients With Active, Moderate-to-severe Crohn's Disease.", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Men or women 18-75 years at the time of consent.\n\n          -  Diagnosis of Crohn's disease at least 3 months prior to screening.\n\n          -  Moderate to severe active Crohn's disease, defined as CDAI >or=220 and <or=450.\n\n        Exclusion criteria:\n\n          -  Complications of Crohn's disease such as strictures, stenoses, short gut syndrome, or\n             any other manifestation that might require surgery.\n\n          -  Presence of ileostomy or colostomy.\n\n          -  Pregnant or nursing women.\n\n          -  Signs or symptoms suggestive of active TB.\n\n          -  History of malignancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031276", 
            "org_study_id": "1311.6", 
            "secondary_id": "2013-002902-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 655066", 
                "description": "multiple high dose BI 655066", 
                "intervention_name": "BI 655066 (high dose)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655066", 
                "description": "multiple low dose BI 655066", 
                "intervention_name": "BI 655066 (low dose)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655066 SC", 
                "description": "multiple  SC dose BI 655066", 
                "intervention_name": "BI 655066 one dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "multiple dose placebo", 
                "intervention_name": "placebo dose", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1311.6.10010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamden", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "1311.6.10003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Orange", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1311.6.10004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "1311.6.10007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chevy Chase", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "1311.6.10005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chesterfield", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "1311.6.10002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "1311.6.10008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }, 
                    "name": "1311.6.32005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "1311.6.32003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium"
                    }, 
                    "name": "1311.6.32001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roeselare", 
                        "country": "Belgium"
                    }, 
                    "name": "1311.6.32004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "1311.6.11001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1311.6.11004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1311.6.11002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Tronche", 
                        "country": "France"
                    }, 
                    "name": "1311.6.33003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France"
                    }, 
                    "name": "1311.6.33001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France"
                    }, 
                    "name": "1311.6.33002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Priest en Jarez", 
                        "country": "France"
                    }, 
                    "name": "1311.6.33005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vandoeuvre-les-Nancy", 
                        "country": "France"
                    }, 
                    "name": "1311.6.33004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "1311.6.53001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "1311.6.53002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1311.6.82004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1311.6.82001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1311.6.82002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1311.6.82003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1311.6.82005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "1311.6.34001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L'Hospitalet de Llobregat", 
                        "country": "Spain"
                    }, 
                    "name": "1311.6.34002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "1311.6.34003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1311.6.44005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1311.6.44001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1311.6.44006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1311.6.44004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle Upon Tyne", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1311.6.44002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oxford", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1311.6.44003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "France", 
                "Ireland", 
                "Korea, Republic of", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066, an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are na\u00efve to, or Were Previously Treated With Anti-TNF Therapy.", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal and Health Products", 
                "Canada: Health Canada", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Ireland: Irish Medicines Board", 
                "Korea: Ministry of Food and Drug Safety", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Spain: Spanish Agency of Medicines", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients achieving clinical remission at week 12, defined as a CDAI score of < 150.", 
            "safety_issue": "No", 
            "time_frame": "week 12"
        }, 
        "removed_countries": {
            "country": "Netherlands"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031276"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients achieving clinical response defined by either a CDAI score of < 150 or a CDAI reduction from baseline of at least 100 points.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Proportion of patients achieving CDEIS remission, defined as a score of 4 or less.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Proportion of patients achieving CDEIS response, defined as a score of 7 or less.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Proportion of patients achieving mucosal healing, defined as the absence of mucosal ulceration.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Proportion of patients achieving deep remission, defined as clinical remission and CDEIS remission.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Proportion of patients achieving reduction of 75% in CDEIS scores from baseline.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Time to flare for patients who achieve deep remission.", 
                "safety_issue": "No", 
                "time_frame": "week 65"
            }, 
            {
                "measure": "Time to CDAI >or= 150 for patients who achieve clinical remission.", 
                "safety_issue": "No", 
                "time_frame": "week 65"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}